Samlyn Capital »

Aeglea Biotherapeutics shares owned by Samlyn Capital

Quarter-by-quarter ownership of Aeglea Biotherapeutics (SYRE) shares owned by Samlyn Capital from 13F filings

Historical chart of Samlyn Capital investment in Aeglea Biotherapeutics

Tip: Access up to 7 years of quarterly data

All positions including Aeglea Biotherapeutics held by Samlyn Capital consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Aeglea Biotherapeutics by Samlyn Capital

Quarter filed Position value Share count Share price at filing
2026-03-31 $20M 397k 50.44

More positions owned by Samlyn Capital

Lpl Financial Holdings (LPLA)
JPMorgan Chase & Co. (JPM)
Primo Brands Corporation Class A Com Shs (PRMB)
Capital One Financial (COF)
Morgan Stanley Com New (MS)
Amazon (AMZN)
Meta Platforms Cl A (META)
Taiwan Semiconductor Manufac Sponsored Ads (TSM)
Blackrock (BLK)
Liberty Media Corp Del Com Lbty One S C (FWONK)
MercadoLibre (MELI)
MKS Instruments (MKSI)
NVIDIA Corporation (NVDA)
Rb Global (RBA)
Live Nation Entertainment (LYV)

View all positions for Samlyn Capital

Top funds holding Aeglea Biotherapeutics

FMR
BlackRock
Rtw Investments
Vanguard Group
Fairmount Funds Management
Perceptive Advisors
VR Adviser
Vanguard Capital Management
Driehaus Capital Management
State Street Corporation
Paradigm Biocapital Advisors
Commodore Capital
TCG Crossover Management
Tang Capital Management
Capital Research and Management Company - Division 3

View all funds holding Aeglea Biotherapeutics